Search filters

List of works by Giorgio Valabrega

A predictive score for optimal cytoreduction at interval debulking surgery in epithelial ovarian cancer: a two- centers experience.

scientific article

A retrospective analysis of the activity and safety of oral Etoposide in heavily pretreated metastatic breast cancer patients

scientific article published on 15 March 2015

Active immunotherapy in HER2 overexpressing breast cancer: current status and future perspectives.

scientific article published on 12 April 2013

Adoptive immunotherapy against ovarian cancer

scientific article

Androgen receptor status predicts development of brain metastases in ovarian cancers.

scientific article published on 12 April 2017

Author Correction: Modeling ErbB2-p130Cas interaction to design new potential anticancer agents

scientific article published on 22 November 2019

Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer

scientific article

CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy

scientific article published on 11 June 2019

Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity.

scientific article

Concurrent radiotherapy does not affect adjuvant CMF delivery but is associated with increased toxicity in women with early breast cancer.

scientific article

Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer ⬇️

scientific article published on October 1, 2012

Cytoreductive Surgery for Heavily Pre-Treated, Platinum-Resistant Epithelial Ovarian Carcinoma: A Two-Center Retrospective Experience

scientific article published on 10 August 2020

Endometrial Cancer Stem Cells: Role, Characterization and Therapeutic Implications

scientific article published on 19 November 2019

ErbB2 and bone sialoprotein as markers for metastatic osteosarcoma cells.

scientific article published on February 2003

HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib

scientific article published on 9 December 2010

Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity?

scientific article published on 06 January 2011

Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients.

scientific article

Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?

scientific article

Immuno-Metabolism and Microenvironment in Cancer: Key Players for Immunotherapy

scientific article published on 21 June 2020

Immunotherapy for Cervical Cancer: Are We Ready for Prime Time?

scientific article published in 2022

Impact of COVID-19 in gynecologic oncology: a Nationwide Italian Survey of the SIGO and MITO groups

scientific article published on 01 November 2020

Metastatic breast cancer subtypes and central nervous system metastases

scientific article published on 30 June 2014

Modeling ErbB2-p130Cas interaction to design new potential anticancer agents

scientific article published on 28 February 2019

Moderate immunohistochemical expression of HER-2 (2+) without HER-2 gene amplification is a negative prognostic factor in early breast cancer

scientific article

Multitarget drugs: the present and the future of cancer therapy

scientific article published in March 2009

New and developing chemical pharmacotherapy for treating hormone receptor-positive/HER2-negative breast cancer.

scientific article published on 20 September 2016

Olaparib as maintenance therapy in patients with BRCA 1-2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome

scientific article published on 04 November 2019

Omission of axillary dissection after a positive sentinel node dissection may influence adjuvant chemotherapy indications in operable breast cancer patients.

scientific article

Oral etoposide in heavily pre-treated metastatic breast cancer: A retrospective series.

scientific article published on 29 January 2018

Outcome of patients with HER2-positive advanced breast cancer progressing during trastuzumab-based therapy

scientific article published on 01 April 2006

Ovarian Cancer Immunotherapy: Turning up the Heat

scientific article published on 15 June 2019

Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions.

scientific article

PARP Inhibitors in Ovarian Cancer.

scientific article published on 5 March 2018

Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer

scientific article published on 13 September 2013

Potential of afatinib in the treatment of patients with HER2-positive breast cancer

scientific article

Recent advances in the development of breast cancer vaccines

scientific article

Recent advances in the medical management of breast cancer: highlights from the 29th San Antonio Breast Cancer Conference San Antonio, TX, USA, 14-17 December 2007

Reprogramming T-cells for adoptive immunotherapy of ovarian cancer

scientific article published on 8 January 2018

Retrospective evaluation of clinical outcomes in patients with HER2-positive advanced breast cancer progressing on trastuzumab-based therapy in the pre-lapatinib era.

scientific article

Role of Cyclin-Dependent Kinase Inhibitors in Endometrial Cancer. ⬇️

scientific article

Role of trastuzumab in the management of HER2-positive metastatic breast cancer.

scientific article

TGFalpha expression impairs Trastuzumab-induced HER2 downregulation

scientific article published in April 2005

TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers

scientific article published on 13 February 2019

TOP2A gene copy gain predicts response of epithelial ovarian cancers to pegylated liposomal doxorubicin: TOP2A as marker of response to PLD in ovarian cancer.

scientific article published on 20 June 2015

The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer

scientific article published on 09 April 2019

Translational Research in Ovarian Cancer

scientific article published on 08 December 2020

Trastuzumab Beyond Progression in Retrospective Analyses: An Issue of Equal Opportunities ⬇️

scientific article published on March 10, 2011

Trastuzumab beyond disease progression: case closed?

scientific article

Trastuzumab treatment in breast cancer

scientific article published on 01 May 2006

Trastuzumab-related cardiotoxicity in the herceptin adjuvant trial

scientific article published on 01 April 2008

Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer.

scientific article published on 17 January 2007

Underuse of anthracyclines in women with HER-2+ advanced breast cancer

scientific article published on 24 June 2010

Veliparib: a new therapeutic option in ovarian cancer?

scientific article published on 10 May 2019

Vinorelbine-based salvage therapy in HER2-positive metastatic breast cancer patients progressing during trastuzumab-containing regimens: a retrospective study

scientific article

Women With Synchronous or Metachronous Lung and Ovarian Cancer: A Multi-Institutional Report

scientific article published on 01 November 2019

Xenopatients show the need for precision medicine approach to chemotherapy in ovarian cancer.

scientific article published on 24 March 2016

p130Cas scaffold protein regulates ErbB2 stability by altering breast cancer cell sensitivity to autophagy

scientific article published on 21 December 2015

Paulina is supported by:

About Paulina

Help